CLAIMS

1. Use of:

(i) elafibranor or a pharmaceutically acceptable salt thereof, and

(ii) Gemcabene, CP-640186, GS-0976, or a pharmaceutical salt thereof;

in the preparation of a combination medicament for treating a cholestatic disease.

2. Use according to claim 1, wherein the combination medicament is a composition comprising components (i) and (ii) and a pharmaceutically acceptable carrier.

3. Use according to claim 1 or 2, wherein the combination medicament is a kit of parts comprising components (i) and (ii), for sequential, separate or simultaneous use.

4. Use according to any one of claims 1 to 3, wherein components (i) and (ii) are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an oinment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

5. Use according to any one of claims 1 to 4, wherein the disease is selected from the group consisting of cholangiopathies such as Primary Sclerosing Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, progressive familial intrahepatic cholestasis type 3 (PFIC3).

6. Use according to claim 5, wherein the disease is selected from the group consisting of PSC and PBC.

7. Use according to claim 6, wherein the disease is PBC.